Recent

% | $
Quotes you view appear here for quick access.

Arrowhead Research Corp. Message Board

  • investron@ymail.com investron Aug 21, 2013 3:10 PM Flag

    There Seems To Be Continued Miscommunication

    Arrowhead's ARC520 demonstrated safety and efficacy in an extremely high bar infection of the closest thing next to man genetically and in term of HBV kinetics, our friend of Tarzan, the chimp, whose relatives previously no less helped us develop the HBV vaccine for man.

    The result was so convincing and stunning the HepB Foundation itself, whose founder discovered and developed said vaccine, delivered the news.

    Which was, gasp, hold on to your seat, functional cure for HBV appeared at hand! Folks, there was and is nothing like it. Period. Nothing that has demonstrated this potentiality anywhere else on the horizon. Period.

    *Cricket chirps*

    The Yahoos didn't know what to make of this. Some questioned what the chimp had anything to do with people. Etc.

    To this day some said if Roche dumped the technology it had to be no good. A troll came by with a totally undemonstrated concept and people are now thinking it could be superior, one shot vs. more than one, about to go on the market and compete with Arrowhead's, etc.

    And the worst of all, ARWR trades at $4 and cents.

    Wow!, you know, I tried.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For what it's worth, here are Dirk's thoughts on the matter, when taking up the discussion of Arrowhead's approach to HBV vs Benitec's.

      "Once you have an equivalent anti-viral cure with a non-gene therapy option that requires only a few months or even years of dosing, it will be hard to justify a gene therapy."

      Linda

      • 2 Replies to latebloomer4140
      • investron@ymail.com investron Aug 21, 2013 8:17 PM Flag

        Take the time to understand what you just read.

        "Once you have an equivalent anti-viral cure with a non-gene therapy option that requires only a few months or even years of dosing, it will be hard to justify a gene therapy."

        Read this again and see if it doesn't tell you what I have been hinting for you to research and find out for yourself?

        Does it, for example, suggest to you in no uncertain term that somehow so-called "ddRNAi" therapy, here directly called what it is, gene therapy (DNA therapy, DNA transplant, etc.) is less desirable even if it would work in one shot? (Which, again, it has not been demonstrated - there are many things to overcome and some issues may never go away.)

        Think about it, how could something that would take more shots, more time, maybe "months, even years of dosing," which is Arrowhead's, be more desirable than what Benitec is hoping to do in one shot? Shocking isn't it?

        Now go back to my original reply to you asking you to do research for yourself before commenting the way you did that it's pretty much the same thing but with possibly one shot advantage which you kept repeating over and over and remarkably refused to budge in spite of my increasingly stronger hints otherwise..

        Final hint: It is not. (That was why I used the word "wrong" flat out to jar you out of the trance.)

        Then write us that post you are capable of, which will lucidly tell people waiting to be spoonfed why Arrowhead's is THE best candidate as I pointed out.

        Once again, it will help gel your understanding and you will be able to tell the next troll off.

      • And he's pretty favorable of the potential for ddRNAi...

    • "A troll came by with a totally undemonstrated concept and people are now thinking it could be superior, one shot vs. more than one, about to go on the market and compete with Arrowhead's, etc."

      You think that's the gist of what I said?

      Well, clearly I didn't communicate my thoughts very well to you, investron. Fair enough...

      Linda

      • 2 Replies to latebloomer4140
      • investron@ymail.com investron Aug 21, 2013 4:53 PM Flag

        Don't worry.

        It's rhetorical.

      • Sometimes - not always - it helps to bring things further into the light and discuss them, rather than to treat everything exactly the same, dismissing everything out of hand.

        I'm actually feeling better about Arrowhead now after looking further into Benitec than I was before. Further, as the main analyst covering Benitec noted, Benitec might even be a company whose sp could benefit from some of Arrowhead's success, not so unlike Arrowhead has seen some benefit with ALNY's recent successes. I'm not ready to take that step yet, but it's now something I'll be considering over time in addition to the recent full position I've now taken in Arrowhead.

        Sentiment: Strong Buy

 
ARWR
6.98+0.24(+3.56%)Mar 27 3:59 PMEDT